Ypsomed today announced clinical study data demonstrating the benefits of its hybrid closed-loop insulin delivery system for pregnant women. Pregnant women with type 1 diabetes and their babies benefitted from the automated insulin delivery system based on the CamDiab CamAPS FX algorithm. The New England Journal of Medicine published these outcomes from Ypsomed’s AiDAPT clinical study. Ypsomed says […]
Ypsomed
Ypsomed has a new CFO, board member
Ypsomed announced today that it selected Samuel Künzli to take over the company’s chief financial officer (CFO) position. Niklaus Ramseier elected to hand over the reins to the CFO position after more than 20 years in the post. The transition begins on March 31, 2024, with Ramseier remaining available to the drug delivery device maker […]
Ypsomed concludes autoinjector supply deal with Novo Nordisk
Ypsomed announced today that it concluded a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors. Burgdorf, Switzerland-based Ypsomed designed the autoinjectors to administer drugs for the self-treatment of metabolic conditions. It intends to deliver variants of its YpsoMate 1mL autoinjector for various drugs undergoing clinical trials in large quantities. This expands its […]
8 drug delivery innovations you should know
Innovations in drug delivery never stop, and over the past 12 months or so a wide variety have been in the spotlight. Constant progress continues in the diabetes space, both in the form of insulin delivery and other drug delivery methods. Elsewhere, we see implants, patches, syringes and more showcasing the many ways we can […]
Ypsomed to expand drug delivery device manufacturing, add 200 jobs
Ypsomed announced today that, at its annual general meeting, its shareholders approved all proposals, including facility expansions. Burgdorf, Switzerland-based Ypsomed develops drug delivery devices, including insulin pumps for those with diabetes. Its YpsoPump represents a leading offering as an automated insulin delivery system compatible with certain software and glucose monitors. Board member Simon Michel confirmed […]
Ypsomed, S3 Connected Health partner to expand digital offerings
Ypsomed announced plans to expand its offerings of digital health solutions for chronic disease therapy together with S3 Connected Health. Dublin, Ireland-based S3 Connected Health specializes as a digital health partner for life science companies. This partnership allows Ypsomed’s biopharma customers to quickly launch therapy-specific digital patient solutions. It enables therapy management support for acute […]
Abbott FreeStyle Libre 3 authorized for automated insulin delivery in UK
Abbott (NYSE:ABT) announced that its FreeStyle Libre 3 continuous glucose monitor (CGM) received UK authorization for use in automated insulin delivery. Authorization enables FreeStyle Libre 3 — Abbott’s newest sensor — to work with the Ypsomed mylife YpsoPump and CamDiab’s CamAPS FX mobile app. The company called this a “major step forward” for type 1 […]
The year ahead in diabetes care: what to expect in 2023
After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023. Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more. You can read all about the biggest diabetes stories […]
Ypsomed, Mediq complete sale of DiaExpert
Ypsomed and Mediq announced today that they completed the sale of mail-order retailer for diabetes care DiaExpert. Germany-based DiaExpert specializes in insulin pump therapy. The companies previously announced the sale of DiaExpert in October. This sale allows Ypsomed to focus on the manufacture and sale of its own medical technologies. That focus continues to narrow […]
The 10 biggest diabetes tech stories from 2022
2022 represented a landmark year for next-generation diabetes tech. Here are the biggest stories from the past year. Some companies picked up major regulatory nods. Others experienced major regulatory setbacks. Partnerships were formed and ended, while mergers and acquisitions came and went. There were many stories to choose from in the world of diabetes tech, […]
